Medocity Collaborates with Leading U.S. Cancer Hospital on Novel Approach to Real-time Patient-Centered Coordinated Care

Newly launched study to measure clinician, cancer patient engagement
and satisfaction with Medocity’s virtual mobile care platform

MORRISTOWN, N.J.–(BUSINESS WIRE)–Medocity Inc. and Dana-Farber Cancer Institute have launched a new
research study to utilize Medocity’s patient-centered mobile solution
for self-care at home with self-assessment and management of symptoms
along with side effects for Gastrointestinal (GI) cancer patients
undergoing treatment.

The unique study uses Medocity’s integrated platforms, iCancerHealth for
patients and Medocity MD for clinicians, to connect patients in
Dana-Farber’s Gastrointestinal Cancers treatment center with their
clinical care team in real-time to manage medications, symptoms and side
effects from treatment. The Principal Investigator at Dana-Farber, Donna
Berry, PhD, RN, stated, “We know from randomized trials that monitoring
and self-care, along with communication facilitators in patients
receiving cancer therapies, result in significant benefit for the
patient; the iCancerHealth platform has the potential to provide exactly
that type of support.”

“We are excited to have Dana-Farber as a partner for this innovative,
patient-centered research study that aligns with our mission to bridge
the gap between clinic and the patient’s home,” said Raj Agarwal, CEO
and President of Medocity. “We believe real-time coordinated care,
supporting early detection of symptoms and side effects with proactive
interventions, will enhance patient care and may reduce overall
healthcare costs including avoidable ER visits and hospitalizations,”
added Agarwal.

Dana-Farber’s clinical care team will utilize the Medocity MD platform
for virtual interaction with study participants for continuity of care
and monitoring between clinical visits using system-generated alerts for
symptoms and side effects. The platform uses algorithm-based management
to facilitate care delivery and communicate effectively with patients in
a secured environment.

The study investigators will measure the feasibility of deploying the
platform to both patients and clinicians. Dana-Farber will enroll 70
cancer patients and up to ten clinicians. The study is expected to
complete by mid 2016.

With iCancerHealth, Medocity aims to:

  • Improve patient experiences by enhancing communication and
    transparency of patient–reported outcomes (PRO) between patients,
    caregivers and clinicians.
  • Enhance patient care at home by providing self-care tools and secured
    messaging, voice and video with the care team.
  • Facilitate peer-powered online community support for cancer patients
    for psychological, social, family and career related impact

About Medocity

Medocity’s mission is to provide a virtual coordinated care platform
that bridges the gap between the clinic and the patient’s home. This is
accomplished by managing the patient’s care utilizing a proprietary,
interactive and rules-based mobile solution designed to optimize the
patient journey, improve quality of care, and effectively reduce
avoidable health care costs in the system. Our vision is to provide a
variety of offerings in multiple disease states that will ultimately
enable transformation and innovation of healthcare delivery and patient

For more information, visit
or access the video guide for iCancerHealth at

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber / Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National
Cancer Institute. Dana-Farber is the top ranked cancer center in New
England, according to U.S. News & World Report, and one of the largest
recipients among independent hospitals of National Cancer Institute and
National Institutes of Health grant funding.


For Medocity:
Cathy Guttman, 973-679-8234
Director, Business Development
Dana-Farber Cancer Institute:

Ellen Berlin, 617-632-4090